Course Experts: Sylvia Truong, PharmD; Eno Inyang, PharmD, BCPS; Lara Abousamra, PharmD, BCPS

Course Description: This course reviews the role of hematopoietic stem cell transplantation (HSCT) in the management of hematologic malignancies, with a focus on patient selection and evidence-based post-transplant maintenance strategies. Learners will evaluate clinical trial data, guideline recommendations, and treatment-related toxicities to optimize maintenance therapy following autologous and allogeneic HSCT.

[DFCI_KEYWORDS] Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Lymphocytes, Lymphadenopathy, Venetoclax, Obinutuzumab, Rituximab, Fludarabine, Bendamustine, Antiplatelet, Anticoagulation, Leukocytosis